This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Cytochrome c oxidase subunit 6A2, mitochondrial.
Human | |
---|---|
Gene Name: | COX6A2 |
Uniprot: | Q02221 |
Entrez: | 1339 |
Belongs to: |
---|
cytochrome c oxidase subunit 6A family |
COX VIa-M; COX6A; COX6AH; COXVIAH; Cytochrome c oxidase polypeptide VIa-heart; cytochrome c oxidase subunit 6A2, mitochondrial; cytochrome c oxidase subunit VIa polypeptide 2; Cytochrome c oxidase subunit VIA-muscle
Mass (kDA):
10.815 kDA
Human | |
---|---|
Location: | 16p11.2 |
Sequence: | 16; NC_000016.10 (31427731..31428360, complement) |
Expressed specifically in heart and muscle.
Mitochondrion inner membrane; Single-pass membrane protein.
This article will give you an overview of Boster Bio's Anti-CX6A2 COX6A2 marker's clinical applications and side effects. To understand the benefits and limitations of this marker, you should first understand its symptomology and potential side effects. We will also talk about the clinical applications of this mark for animal and human research. Here are some of most popular uses of the COX6A2 marker.
The COX6A2 marker, also known as CX6A2, identifies the level of the protein's expression in the body. The COX6A2 protein regulates cellular metabolism and is linked to asthma and other allergic diseases. It has been implicated for the development of many cancers. The eosinophils, which are responsible for the aging process, express the COX6A2 gene.
The COX6A2 marker can be used to detect metabolic disease. It is found in the BAT and skeletal muscle. Its absence protects mice against metabolic changes. It has been implicated in obesity, glucose intolerance, and other metabolic disorders. Its clinical applications continue to grow. Here are some of the key benefits of this marker. It can be used to identify the disease and also aid in the creation of new drugs.
This biomarker is useful in many aspects of psychiatric treatment. Although the exact biochemical mechanism is still unknown, it can be detected as a biomarker in the blood of schizophrenia patients. The marker can be used to assess severity of symptoms and to help with disease monitoring and patient stratification. It is thought to affect the production and use of cellular energy via COX6A2.
The COX6A2 Subunit is a component that is present in both mitochondrial and pulmonary tissues. COX6A is an important regulator of complex expression and activity. COX10 plays a major role in the early steps of complex formation. COX6A, a subunit that is late-assembled and essential for the synthesis function complex IV, is however important.
The COX6A2 gene is located on chromosome 16 and encodes a 97-amino acid polypeptide. The gene can be divided into three parts. Moreover, Bachman et al. (1997) identified a transcription factor binding site in the COX6AH promoter region. They also found a flanking 5-prime COX6AH.
The exosomal COX6A2 level is correlated with symptom severity in patients with Psy-D. In addition, patients with Psy-D have an inverse correlation between their exosomal and severity levels of symptoms. It is important to keep in mind that the two genes may not be related. It is possible that there is a correlation between these markers.
Researchers have discovered a biomarker for schizophrenia. This marker can identify patients with schizophrenia by detecting changes in miR-137 and COX6A2. These markers correlate with the severity of clinical symptoms as well cognitive deficits and functional abilities in daily life. Researchers hope that this biomarker can help them better understand schizophrenia. The first step in finding a reliable biomarker of psychosis is to understand the neurobiology of COX6A2.
One study found that mice without the COX6A2 genes have a protective effect on obesity and other metabolic diseases. In addition, mice lacking the COX6A2 gene were protected from a high-fat diet-induced obesity. The study also revealed that mice lacking the COX6A2 gene also showed improved insulin resistance and decreased subcutaneous fat mass. The mice that did not have this gene were protected from obesity, diabetes, and other complications.
Interestingly, the gene Cox6a2 isn't expressed in the thermogenic adipose tissues. Its signals in SC WAT and mesenteric samples are derived from public studies. Moreover, the COX6A2 signal correlates with muscle markers, such as UCP1, in BAT and mesenteric samples. These results suggest that this unit may be responsible to weight gain in humans.
The COX6A2 mark has side effects that aren't seen in other COX6A2 mice. The gene may increase the risk of cardiovascular disease by increasing obesity. It could also play a significant role in glucose metabolism. However, further research is required to identify its exact mechanism. Side effects of COX6A2 mutants in humans may be more subtle and likely to be triggered from other metabolic disorders.
Complex IV of a respiratory chain contains the Cox6a2 protein. The loss of this protein increases ROS production and AMPK and PGC-1a activity in skeletal muscle. It also induces transcription of uncoupling proteins within skeletal muscle. This results in increased energy expenditure, enhanced thermogenesis and a change in the type of muscle fibers. These metabolic changes could also lead to insulin sensitization.
PMID: 1327966 by Fabrizi G.M., et al. Differential expression of genes specifying two isoforms of subunit VIa of human cytochrome c oxidase.
PMID: 9177785 by Bachman N.J., et al. Structure of the human gene (COX6A2) for the heart/muscle isoform of cytochrome c oxidase subunit VIa and its chromosomal location in humans, mice, and cattle.